Fig. 2From: A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopeniaPlatelet counts at every scheduled visit during the 10-week double-blind treatment period. HETROM-2.5, the dose was titrated from an initial dosage of once-daily 2.5Â mg hetrombopag; HETROM-5, the dose was titrated from an initial dosage of once-daily 5Â mg hetrombopag. The data are shown as means (standard errors)Back to article page